###### Strengths and limitations of this study

-   To the best of our knowledge, it is the first meta-analysis to explore the relationship between sarcopenia and all-cause mortality among elderly nursing home residents.

-   An extensive search process in an electronic database was used and methodological quality was assessed; we also tested the heterogeneity and publication bias and performed sensitivity analysis among the included studies.

-   This systematic review and meta-analysis assessed the overall quality of the evidence by using Newcastle-Ottawa Scale approach for prospective observational studies and conducted a meta-analysis and subgroup analysis.

-   The number of studies included in this analysis was insufficient, and the size sample was relatively small.

-   Different cut-off values for the muscle mass might affect the relationship between sarcopenia and all-cause mortality.

Introduction {#s1}
============

Sarcopenia is a common syndrome characterised by a loss of muscle mass and strength with functional impairment and adverse health outcomes due to cumulative deficits of multiple systems.[@R1] Nursing home residents are at a particularly high risk for sarcopenia.[@R2] According to studies, the prevalence of sarcopenia was 1%--29% for community-dwelling older adults, 14%--85.4% in nursing homes[@R2] and 10%--24.3% for those in hospitals.[@R5] Sarcopenia leads to a worse outcome in elderly people, including physical disability, falls, fractures, poor quality of life, mortality and hospitalisation.[@R6] Among these, mortality might be considered the most important outcome in elderly people. So far, the relationship between mortality and operational criteria that define sarcopenia has been well described in community-dwelling older adults and hospitalised patients. A recent meta-analysis study, Liu *et al,* [@R9] analysed sarcopenia and mortality and concluded that sarcopenia is a predictor of all-cause mortality among community-dwelling older people. However, there is no consistent conclusion regarding the relationship between sarcopenia and mortality among nursing home residents. It has been shown that the mortality rate in nursing homes[@R10] is approximately twofold higher than that in the community[@R11]; therefore, it is very important to confirm the risk factors for mortality among nursing home residents.

Several studies found that elderly people with sarcopenia were predictors of all-cause mortality among nursing home residents.[@R14] However, some studies did not find any significant relationship between sarcopenia and all-cause mortality.[@R16] Given the observed contradictory relationship between sarcopenia and all-cause mortality among nursing home residents in some studies, further studies are needed. However, no systematic reviews of meta-analysis studies on this topic have been conducted in the literature. Therefore, our study aims to identify and compare prospective cohort studies examining sarcopenia as a predictor of all-cause mortality among nursing home residents according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines.

Materials and methods {#s2}
=====================

This meta-analysis was conducted according to the MOOSE guidelines.[@R20]

Search strategy and selection criteria {#s2a}
--------------------------------------

A systematic literature search was conducted in MEDLINE (via PubMed 1946 to November 2017), EMBASE (via EMBASE November 2017) and Cochrane CENTRAL Library (via Cochrane Library November 2017). The search strategy was tailored according to each database. We used a combination of keywords such as mortality (mortality\*), OR death (death\*), OR survival (survival\*) and sarcopenia (sarcopenia\*), as well as MeSH terms. We also used subject terms and truncation symbols in our search strategy. We searched the potential grey studies through Google Scholar. Furthermore, we carried out a manual search on the references of included studies. The full search strategy for three databases has been provided as a supplementary file.

Study selection {#s2b}
---------------

These studies which were identified by our search strategy were reviewed by teams of two independently blinded investigators (XZ and CW) who evaluated each title and abstract. In case of disagreement (whether to include or exclude studies), the issue was discussed and a third reviewer evaluated the study until the reviewers reached consensus.

Inclusion and exclusion criteria {#s2c}
--------------------------------

The following eligibility and exclusion criteria were prespecified. Studies had to fulfil the following four inclusion criteria: (1) prospective cohort studies, (2) studies investigating whether sarcopenia was a predictor of mortality, (3) studies reporting clear diagnostic criteria for sarcopenia, (4) type of participant: elderly adult in nursing home or nursing care. Exclusion criteria were as follows: (1) type of participant: community-dwelling older people (aged 65 years or older) or hospitalised older people; (2) article type: only abstract, letters and laboratory research; review articles; (3) insufficient data; (4) other languages of studies, except English; (5) no clear definition of sarcopenia.

Data extraction {#s2d}
---------------

Two investigators (XZ, CW) independently abstracted the data from the selected studies using a standardised data abstraction form. The following information was extracted from included papers: author, country, year of publication, demographic characteristics of participants (eg, sample size, male proportion), measurement methods of sarcopenia, follow-up period, adjusted variable and study quality. The reviewers cross-checked all extracted data. Disagreements were resolved by discussion until consensus was reached.

Assessment of risk bias {#s2e}
-----------------------

Assessment of risk of bias was performed by two independent reviewers (XZ, CW) according to the Newcastle-Ottawa Scale (NOS)[@R21]: (1) representativeness of the exposed cohort, (2) comparability of group, (3) blinding of investigators who measured outcomes, (4) the time and completeness of follow-up, (5) contamination bias and (6) other potential sources of bias. The total score of the scale is 9 points. When the total score is ≥5 points, it is considered as a high-quality research.

Statistical analysis {#s2f}
--------------------

The STATA V.14.0 was independently used for all analyses by two authors (XZ, QD). HRs, OR and their 95% CIs of mortality for sarcopenia compared with non-sarcopenia were extracted from studies for future meta-analysis. Risk ratio (RR) was considered equivalent to HR in our prospective cohort studies, which was reported in Willi's[@R22] study and Mahmoud's study.[@R23] If a study reported the effect size as an OR, it was converted to RR using a previously described formula.[@R24] All the effect of HR or RR was converted to ln(HR) or ln(RR) for ratio in meta-analysis, subgroup analyses were conducted by different diagnosis tools for muscle mass and follow-up period if there was more than one study in the subgroup. The statistical heterogeneity among the included studies was examined with Cochran's Q statistic using χ^2^ and I^2^ statistics, and I^2^ value of 25%, 50% and 75% represented the cut-off of low, moderate and high heterogeneity, respectively. If heterogeneity was found to be reasonably high between studies, the random-effects model was used. Otherwise, the fixed-effects model was used. Results were illustrated using forest plots, and Begg's test was done to plot the log HR against its SE for assessment of potential publication bias.

Patient and public involvement {#s2g}
------------------------------

The patients or public were not involved in the study.

Results {#s3}
=======

Search results {#s3a}
--------------

The literature search strategy initially identified 2292 articles. After removal of duplicates, 1965 articles were screened for potential eligibility. A total of 85 publications remained for further consideration. Then we screened titles and abstracts and removed unrelated articles. Of these articles, 30 were removed because of non-cohort studies (eg, review articles, conference documents, cross-sectional study, case--control study), and six were removed because they had no clear definition of sarcopenia; moreover, 41 were removed on account of different study population: community-dwelling older people, patients in hospital and used the same cohorts (n=2). These studies were screened according to the predefined inclusion and exclusion criteria for inclusion in the meta-analysis, resulting in a total of six eligible studies ([figure 1](#F1){ref-type="fig"}).

![The flow diagram of studies selection. LMM, low muscle mass.](bmjopen-2017-021252f01){#F1}

Included studies {#s3b}
----------------

Six prospective cohort studies were included in our meta-analysis with 1494 total participants. Study characteristics of included papers are displayed in [table 1](#T1){ref-type="table"}. Two studies were conducted in Turkey,[@R17] one study in Italy,[@R15] one study in Australia,[@R16] one study in Belgium[@R14] and one study in Israel[@R19]. All the studies selected all-cause mortality as the clinical outcome and five studies used the sarcopenia criteria of European Working Group for Sarcopenia (EWGSOP), the other[@R19] used National Institute of Healt (NIH)-sponsored workshop[@R25] to diagnose sarcopenia. The EWGSOP[@R1] recommends using the presence of both low muscle function (strength or performance) and low muscle mass for the diagnosis of sarcopenia. Thus, diagnosis of sarcopenia in the present study required the documentation of low muscle mass plus the documentation of either low muscle strength or low physical performance. The prevalence of sarcopenia ranged from 32.8% to 73.3%. The largest study consisted of 662 men and women, and the smallest cohort had only 58 individuals. Follow-up periods were no longer varying from 6 months to 24 months, and the adjusted HR was displayed in four studies, and one used OR and the other used RR. [Table 2](#T2){ref-type="table"} shows the different tools and cut-off of muscle mass, muscle strength and physical performance. Four studies used bioelectrical impedance analysis (BIA) as a diagnostic criterion for muscle mass, and the other two studies used anthropometric measures as diagnostic criteria.

###### 

Summary of included studies on sarcopenia associated with all-cause mortality

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author           Country     Year   Male, %   Sample no   Age of patients, years   Prevalence, %   Follow-up period   mortality rate, %   Effect\   Adjusted or crude\                                                                                                                                                     Quality\*
                                                                                                                                            measure   HR/OR                                                                                                                                                                  
  ---------------- ----------- ------ --------- ----------- ------------------------ --------------- ------------------ ------------------- --------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Saka\            Turkey      2016   51        402         78.0±7.9                 73.3            12 months          16.2                HR        Adjusted                                                                                                                                                               8
  *et al* [@R17]                                                                                                                                                                                                                                                                                                             

  Yalcin\          Turkey      2017   54.3      141         79.17±7.99               53.9            24 months          23.4                HR        Age, sex, BMI, Calf circumference, MMSE, MNA, cerebrovascular diseases, osteoarthritis, chronic obstructive pulmonary disease, activity of daily living impairment,\   7
  *et al* [@R18]                                                                                                                                      diabetes,\                                                                                                                                                             
                                                                                                                                                      dementia.                                                                                                                                                              

  Landi\           Italy       2012   25        122         84.1±4.8                 32.8            6 months           21.3                HRs       Age, sex, cerebrovascular diseases, osteoarthritis, chronic obstructive pulmonary disease,\                                                                            8
  *et al* [@R15]                                                                                                                                      activity of daily living impairment                                                                                                                                    

  Henwood\         Australia   2017   29.3      58          85.7±8.2                 51.7            18 months          21.6                RR        Age, sex, BMI, MNA, physical activity                                                                                                                                  6
  *et al* [@R16]                                                                                                                                                                                                                                                                                                             

  Buckinx\         Belgium     2018   27.5      662         83.2±8.99                36.2            12 months          15.9                OR        Age, sex, BMI, frailty, waist circumference,\                                                                                                                          7
  *et al* [@R14]                                                                                                                                      calf circumference,\                                                                                                                                                   
                                                                                                                                                      arm circumference,\                                                                                                                                                    
                                                                                                                                                      wrist circumference,\                                                                                                                                                  
                                                                                                                                                      walking support,\                                                                                                                                                      
                                                                                                                                                      drugs consumed,\                                                                                                                                                       
                                                                                                                                                      medical history,\                                                                                                                                                      
                                                                                                                                                      MMSE,\                                                                                                                                                                 
                                                                                                                                                      Minnesota, MNA,\                                                                                                                                                       
                                                                                                                                                      body fat, SF-36,\                                                                                                                                                      
                                                                                                                                                      EuroQol five dimensions,\                                                                                                                                              
                                                                                                                                                      EuroQol-Visual Analogue Scale,\                                                                                                                                        
                                                                                                                                                      Katz score, fear of falling, Tinetti test, TUG test, SPPB test, gait speed, grip strength, peak expiratory flow, isometric strength                                    

  Kimyagarov\      Israel      2012   41.2      109         84.9±7.4                 40.3            12 months          61.5                HR        Age, sex, BMI\                                                                                                                                                         7
  *et al* [@R19]                                                                                                                                      Charlson Comorbidity Index                                                                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

European Working Group for Sarcopenia in Older Persons defines sarcopenia in men as ALM adjusted for height squared \<7.25 kg/m^2^ combined with low hand grip strength (\<30 kg) and/or low gait speed (\<0.8 m/s).

\*Quality of the studies was assessed with Newcastle-Ottawa Scale (NOS).

BMI, body mass index; MMSE, Mini-Mental State Examination; MNA, Mini-Nutritional Assessment; RR, risk ratio; SF-36, 36-item Short Form Health Survey Questionnaires; SPPB test, short physical performance battery; TUG test, timed up and go.

###### 

Study and Sarcopenia criteria

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                Sarcopenia criteria      Item, tool, cut-off points   Ref                                                                                                                                                           
  -------------------- ------------------------ ---------------------------- ----------------------------------------------------------- ----------------------------- -------------------- ----------------------------------- ---------- --------
  Yalcin *et al*       EWFSOP                   BIA                          Men: SMI ≤8.87 kg/m^2^\                                     Hand grip strength            Men: HGS\<30 kg\     Gait speed: 4 m                     ≤0.8 m/s   [@R18]
                                                                             Women: SMI ≤6.42 kg/m^2^                                                                  Women: HGS\<20 kg                                                   

  Buckinx *et al*      EWFSOP                   BIA                          Men: SMI ≤8.87 kg/m^2^\                                     Hand grip strength            None                 SPPB: short physical performance\   ≤0.8 m/s   [@R14]
                                                                             Women: SMI ≤6.42 kg/m^2^                                                                                       battery                                        

  Henwood *et al*      EWFSOP                   BIA                          Men: SMI \<8.87 kg/m^2^\                                    Hand grip\                    Men: HGS\<30 kg\     SPPB                                ≤0.8 m/s   [@R16]
                                                                             Women: SMI \<6.42 kg/m^2^                                   strength                      Women: HGS\<20 kg                                                   

  Saka *et al*         EWFSOP                   anthropometric measures      CC \<31 cm in men and women\                                Hand grip\                    Men: HGS\<30 kg\     Gait speed: 4 m                     ≤0.8 m/s   [@R17]
                                                                             MUAMC \<23.8 cm in men\                                     strength                      Women: HGS\<20 kg                                                   
                                                                             MUAMC \<23.3 cm in women                                                                                                                                      

  Kimyagarov *et al*   NIH-sponsored workshop   anthropometric measures      SMM index: (males) \<10.5 kg/m^2^ (females) \<8.5 kg/m^2^   Manual muscle testing (MMT)   MMT^\*^score \<106   None                                None       [@R19]

  Landi *et al*        EWFSOP                   BIA                          Men: SMI \<8.87 kg/m^2^\                                    Hand grip\                    Men: HGS\<30 kg\     Gait speed: 4 m                     ≤0.8 m/s   [@R15]
                                                                             Women: SMI \<6.42 kg/m^2^                                   strength                      Women: HGS\<20 kg                                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*MMT: an isometric semiquantitative measurement of eight limb muscles groups, in which muscle strength has subjective grades.

On the classic 0--5 point scale, the lowest grade (0) indicates no contractility or muscle activation, and the highest possible grade (160 points) represents full resistance.

BIA, bioelectrical impedance analysis; CC, calf circumference; EWFSOP, European Working Group for Sarcopenia; HGS, handgrip strength; MUAMC: mid upper arm muscle circumference SMI: Skeletal Muscle Index obtained by absolute skeletal muscle mass divided by height by meters squared (kg/m2).

Quality assessment {#s3c}
------------------

The methodological quality evaluation using NOS of all items is shown in [table 3](#T3){ref-type="table"}. The score of each study ranged from 6 to 8. The scores of five studies were more than 7.

###### 

Result of the Newcastle-Ottawa scale quality assessment

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Newcastle-Ottawa Scale                                                     Saka *et al*                                                      Yalcin *et al*   Landi\    Kimyagarov *et al*   Henwood *et al*   Buckinx *et al*   
                                                                                                                                                                *et al*                                                            
  -------------------------------------------------------------------------- ----------------------------------------------------------------- ---------------- --------- -------------------- ----------------- ----------------- ---
  Selection (4)                                                              Representativeness of the exposed cohort                          1                1         1                    1                 1                 1

  Selection of the non-exposed cohort                                        1                                                                 1                1         1                    1                 1                 

  Ascertainment of exposure                                                  1                                                                 1                1         1                    1                 1                 

  Demonstration that outcome of interest was not present at start of study   1                                                                 1                1         1                    1                 1                 

  Comparability (2)                                                          Comparability of cohorts on the basis of the design or analysis   2                1         2                    1                 0                 1

  Outcome (3)                                                                Assessment of outcome                                             1                1         1                    1                 1                 1

  Was follow-up long enough for outcome to occur                             0                                                                 0                0         0                    0                 0                 

  Adequacy of follow-up of cohorts                                           1                                                                 1                1         1                    1                 1                 

  Quality (9)                                                                Total                                                             8                7         8                    7                 6                 7
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sarcopenia as a predictor of mortality {#s3d}
--------------------------------------

### Meta-analysis of studies {#s3d1}

Six studies examined the association between sarcopenia and mortality among nursing home residents. The pooled HRs values were calculated by fixed-effects models. As shown in [figure 2](#F2){ref-type="fig"}, the HR of all-cause mortality for sarcopenia versus non-sarcopenia was 1.86 (95% CI 1.42 to 2.45, p\<0.001). No significant heterogeneity was observed across these studies (Q-value=4.82, df=5, I^2^=0%, p=0.438).

![Meta-analysis of the association between sarcopenia and mortality among older nursing home residents.](bmjopen-2017-021252f02){#F2}

### Subgroup analysis {#s3d2}

The six studies with HR of all-cause mortality risks for sarcopenia among nursing home residents were further analysed by subgroup. [Figure 3](#F3){ref-type="fig"} compares all-cause mortality risk stratified by length of follow-up for sarcopenia. Two studies that followed up 231 cases for a period of less than 1 year (pooled HR 1.85, 95% CI 0.95 to 3.60, p=0.070); whereas the analysis of other four studies that followed up 1263 cases for a period of 1 year or more (pooled HR 1.87, 95% CI 1.38 to 2.52, p\<0.001). [Figure 4](#F4){ref-type="fig"} shows sarcopenia was significantly associated with the risk of mortality among nursing home residents when using BIA to diagnose muscle mass (pooled effect size=1.88, 95% CI 1.39 to 2.53, p\<0.001), whereas it was not associated when using anthropometric measures to diagnosis muscle mass (pooled effect size=1.79, 95% CI 0.89 to 3.59, p=0.100).

![Subgroup analyses of the meta-analysis according to length of follow-up.](bmjopen-2017-021252f03){#F3}

![Subgroup analyses of the meta-analysis according to different diagnosis tools for muscle mass.](bmjopen-2017-021252f04){#F4}

### Publication bias assessment {#s3d3}

There was no significant publication bias among the studies using Begg's test: p=0.386 ([figure 5](#F5){ref-type="fig"}).

![Funnel plot of sarcopenia and all-cause mortality among older nursing home residents.](bmjopen-2017-021252f05){#F5}

### Sensitivity analysis of all studies {#s3d4}

We conducted a sensitivity analysis of sarcopenia and mortality by omitting one of the included studies each time, and pooling the others together to find which study would influence the main pooled HR. No statistically significant changes were found, as shown in [figure 6](#F6){ref-type="fig"}.

![Sensitivity analysis of all studies.](bmjopen-2017-021252f06){#F6}

Discussion {#s4}
==========

In this meta-analysis, we found evidence suggesting the risk of all-cause mortality among nursing home residents with sarcopenia was higher than that among nursing home residents without sarcopenia. To the best of our knowledge, this is the first meta-analysis to explore the relationship between sarcopenia and all-cause mortality among nursing home residents. Our study indicated assessing sarcopenia is really important among the elderly that live in nursing homes.

Liu *et al* [@R9] implemented a systematic review and meta-analysis regarding the association of sarcopenia with mortality in 2016, published in 2017. However, this review included a population entirely of community-dwelling older people. So far, Chang and Lin[@R26] and Beaudart *et al* [@R27] both performed a systematic review to evaluate the link between sarcopenia and all-cause mortality; however, there were some methodological shortcomings, such as various diagnostic criteria of sarcopenia, crude ORs as effect, various population involving community-dwelling older people and hospitalised patients. Although a subgroup of nursing home residents was analysed in Beaudart's study, there are only two studies that were assessed, which may be underestimated or overestimated their result. Our review included six studies which focus only on the association of mortality and sarcopenia in nursing home residents. The results were stable and reliable after we tested the heterogeneity and publication bias and performed sensitivity analysis among the included studies.

This meta-analysis of six cohort studies shows sarcopenia is an important predictor of all-cause mortality among nursing home residents. The pooled HR value of all-cause mortality was 1.86 (95% CI 1.41 to 2.45, p\<0.001, I^2^=0%). The small I^2^ suggesting no significant heterogeneity was shown across these studies. In addition, our study's pooled HR value is higher than that of Liu *et al* [@R9] (1.60, 95% CI 1.24 to 2.06); the primary reason was the different type of population. Those living in a nursing home usually had worse heath conditions and more comorbidities, more disability and more geriatric syndromes, such as cognitive dysfunction and malnutrition.[@R17] This comprehensive risk factor may aggravate the process of sarcopenia.

In our present study, the prevalence of sarcopenia varied from 32.8% to 73.3%. The difference was mainly due to the mean age, various population and different diagnostic tools, particularly the ways that researchers measured muscle mass. A previous study showed that sarcopenia was associated with mortality when BIA was used to diagnose muscle mass.[@R31] In this present study, we confirmed that sarcopenia was associated with all-cause mortality using BIA to diagnose muscle mass; however, the association was not found when using anthropometric measures. According to the EWGSOP,[@R1] BIA is the most common tool for diagnosing muscle mass; moreover, the test is inexpensive, easy to use, readily reproducible and appropriate for both ambulatory and bedridden patients, which may be considered a portable alternative to dual-energy X-ray absorptiometry in nursing homes. However, the method of anthropometric measures was based on mid-upper-arm circumference and skin fold thickness[@R26] [@R32]; therefore, age-related changes in fat deposits and loss of skin elasticity contribute to errors of estimation in older nursing home residents, which are prone to produce errors.[@R33] Furthermore, anthropometric measures were not recommended for routine use in the diagnosis of sarcopenia.

It has been demonstrated that length follow-up could influence the association between sarcopenia and mortality.[@R9] Our study showed that the subgroup of length of follow-up analysis demonstrated that follow-up period of 1 year or more was associated with all-cause mortality (pooled HR 1.87, 95% CI 1.38 to 2.52, p\<0.001); however, it was not found with the follow-up period of less than 1 year (pooled HR 1.85, 95% CI 0.95 to 3.60, p=0.070). It is noticed that there were only 231 cases in the two studies with the follow-up period of less than 1 year and it is likely that the numbers of studies and included cases for short-term analysis were too small to have a significant result. Therefore, more perspective cohort studies about this issue must be conducted in the future.

The underlying mechanisms between sarcopenia and a higher risk of all-cause mortality were unable to draw a conclusion; some aspects should be mentioned at least. First, the association between sarcopenia and mortality may be explained by the hypothesised adverse effects of a low muscle mass in older people. Several studies showed that low muscle mass is highly associated with increased mortality.[@R34] In addition, elderly people in nursing homes are at high risk of malnutrition,[@R37] which aggravates low muscle mass, resulting in an increased mortality rate. Second, sarcopenia is linked to multiple factors ranging from ageing process,[@R38] multiple chronic health conditions, unhealthy lifestyle, [@R39] hormonal factors, [@R40] inflammation[@R41] and so on.[@R42] Meanwhile, the above factors are considered to be linked with mortality and the development of multifactor worsened the situation of sarcopenia, leading to a passive adaptation to adversity or external stressors which in turn generate increased poor adverse outcomes.[@R43] Third, according to the study of Fried *et al,*[@R44] sarcopenia played a critical aetiologic role in the frailty process, which is related, through frailty, to pernicious consequences, for instance, recurrent falls, bone fracture, disability, multiple emergency room visits and hospital admissions and eventually death.[@R45] Moreover, sarcopenia is considered to increase the risk of falls among the elderly,[@R47] and falls were the major causes of death in nursing home residents.[@R48] Sarcopenia is a geriatric syndrome rather than a disease; the mechanism of sarcopenia is very complex, which needs more research to explore.

Our meta-analysis review has multiple strengths and some limitations. One strength was that we used an extensive search process in electronic databases and assessed methodological quality and tested the heterogeneity and publication bias among the included studies. Another strength was that the included original studies were all of prospective design, which minimised the possibility of recall bias and selection bias. However, our study also has some limitations. First, two included studies did not directly report the HR in the sarcopenia group versus the non-sarcopenia group, but used an approximation of OR to RR, and from RR to HR in the sarcopenia group, which might not show an accurate HR value. Therefore, this approach may lead to method heterogeneity. Another concern was that the cut-off for the muscle mass was different in some studies, which caused the prevalence of sarcopenia to be various, thus potentially influenced the result. Third, the number of included studies in this analysis was insufficient, and the sample size was relatively small. Fourth, we ignored the different adjusted confounding factors of the derived HR from different studies. Fifth, the language of studies was limited to English, and consequently some data from important studies published in other languages have been ignored, which may result in potential language bias. In addition, the follow-up was relatively short for the necessary latency, which may underestimate the results.

Conclusion {#s5}
==========

This study provides evidence that sarcopenia is a significant predictor of all-cause mortality among nursing home residents based on the comprehensive systematic review and meta-analysis. Further studies need to be provided with evidence for specific interventions to prevent and treat sarcopenia, which can reduce mortality in people living in a nursing home [Supplementary file 1](#SP1){ref-type="supplementary-material"}.

10.1136/bmjopen-2017-021252.supp1

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

The authors thank the staffs of the Department of Emergency Medicine, people's hospital of Baoan, Shenzhen for their guidance and support.

XZ and CW contributed equally.

**Contributors:** XZ was responsible for producing the initial draft of the manuscript. CW was responsible for data extraction and for producing the initial draft of the manuscript. QD was responsible for data extraction. WZ was responsible for screening the papers and quality assessment. XX was responsible for screening the papers. YY was responsible for quality assessment, statistical analysis and revision of the manuscript. All the authors approved the final version of the manuscript.

**Funding:** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests:** None declared.

**Patient consent:** Not required.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** All the data can obtain in the electronic databases (PubMed, EMBASE and the Cochrane Library).
